+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Phase 3
Age: 18Years +
All Genders
ID07219238

Evaluating GEH300079 68Ga PETCT Imaging for Detecting Peritoneal Carcinomatosis in Patients With Primary Colorectal, Gastric, Ovarian, or Pancreatic Cancers

Led by GE Healthcare · Updated on 2026-06-17

175

Participants Needed

2

Research Sites

8 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the diagnostic performance of GEH300079 68Ga PETCT imaging in patients with primary colorectal, gastric, ovarian, or pancreatic ductal adenocarcinoma PDAC cancers who have known or suspected peritoneal carcinomatosis PC. This Phase 23, open-label, multicenter trial aims to compare this imaging method to the standard of care SoC imaging in detecting PC, with Phase 2 focusing on dose optimization and Phase 3 confirming safety and efficacy specifically for colorectal, gastric, and ovarian cancers. Participants receive a single intravenous injection of GEH300079 68Ga at a target dose of 3.6 MBqkg followed by PETCT scans approximately 60 minutes after injection, covering from the head to mid-thigh over 20 to 30 minutes. In Phase 2, additional scans may be done at 15 minutes and 3 hours post-injection for some participants. The study has two cohorts in Phase 2 one with colorectal, ovarian, and gastric cancers, and another with PDAC, with Phase 3 focusing on the first group. During the study, participants undergo PETCT imaging and standard imaging assessments to compare detection accuracy. Researchers evaluate per-region sensitivity and specificity of GEH300079 68Ga PETCT versus SoC images, correlate imaging with surgical findings, and assess various quantitative imaging parameters. Safety and image quality are monitored, and the study may influence treatment planning. Participation lasts from initial imaging through follow-up assessments, up to the studys completion in 2029.

CONDITIONS

Brief Title

Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)

Research Team

M

Michelle Straszacker

C

Christopher Buckley

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here